将TIGIT阻塞与MDSC抑制相结合,通过激活抗瘤免疫,阻止乳腺癌骨转移
Lea Monteran1, Nour Ershaid1, Ye'ela Scharff1
1Department of Pathology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Cancer discovery
|March 1, 2024
概括
向颗粒细胞和T细胞相互作用,特别是TIGIT和IL1β,有效地减少了小鼠乳腺癌骨转移的发生. 这种方法重新激活了抗瘤免疫力,并在人体样本中显示出治疗骨转移的希望.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症转移 癌症转移
背景情况:
- 骨转移是乳腺癌的常见和不可治愈的并发症,导致患者的显著发病率.
- 骨转移中的免疫微环境在疾病进展和治疗耐药性方面发挥着关键作用.
研究的目的:
- 用小鼠模型研究乳腺癌骨转移期间的动态免疫变化.
- 为了确定关键的细胞和分子参与者驱动免疫抑制在骨转移的利基.
- 评估准乳腺癌骨转移中确定的途径的治疗潜力.
主要方法:
- 利用一种具有免疫能力的小鼠模型对自发性乳腺癌骨转移进行了研究.
- 在各个阶段进行了免疫转录组对骨转移性病变和骨髓的分析.
- 分析了免疫细胞相互作用,专注于粒细胞和T细胞.
- 在体内针对特定的信号通路 (PD-1,TIGIT) 和细胞因子 (IL1β).
- 人类骨转移患者样本中的验证结果.
主要成果:
- 在整个骨转移过程中揭示了动态的免疫转录组变化.
- 鉴定出颗粒细胞和T细胞之间的显著交叉交谈,创造了一个免疫抑制的微环境.
- 证明了向TIGIT和IL1β途径减弱了骨转移,并通过重新激活抗瘤免疫来改善存活率.
- 在人类骨转移样本中证实了TIGIT和IL1β的突出性.
结论:
- 颗粒细胞和T细胞之间的相互作用对于塑造免疫抑制性骨转移性微环境至关重要.
- 共同准TIGIT和IL1β是一种有前途的治疗策略,可以抑制乳腺癌骨转移.
- 这种方法有可能通过调节免疫反应来治疗人类骨转移.
相关概念视频
01:27Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K